Reduction in infection-related mortality since modifications in the regimen of medical abortion
- PMID: 24405798
- PMCID: PMC3965643
- DOI: 10.1016/j.contraception.2013.11.020
Reduction in infection-related mortality since modifications in the regimen of medical abortion
Abstract
Background: From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24-48 h later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions.
Methods: We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies.
Results: The mortality rate dropped significantly in the 81-month period after the joint change to (1) buccal misoprostol replacing vaginal misoprostol and (2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66-month period), from 1.37/100,000 to 0.00/100,000, P=.013 (difference=1.37/100,000, 95% CI 0.47-4.03 per 100,000).
Conclusion: The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage.
Significance: Deaths from infection following medical abortion declined to zero after a change in the regimen.
Keywords: Buccal misopristol; Clostridia; Doxycycline; Medical abortion; Mortality.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Rates of serious infection after changes in regimens for medical abortion.N Engl J Med. 2009 Jul 9;361(2):145-51. doi: 10.1056/NEJMoa0809146. N Engl J Med. 2009. PMID: 19587339 Free PMC article.
-
Severity of infection following the introduction of new infection control measures for medical abortion.Contraception. 2011 Apr;83(4):330-5. doi: 10.1016/j.contraception.2010.08.022. Epub 2010 Oct 8. Contraception. 2011. PMID: 21397090 Free PMC article.
-
Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days.Contraception. 2009 Sep;80(3):282-6. doi: 10.1016/j.contraception.2009.03.010. Epub 2009 May 2. Contraception. 2009. PMID: 19698822 Free PMC article.
-
[Misoprostol: off-label use in the first trimester of pregnancy (spontaneous abortion, and voluntary medical termination of pregnancy)].J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):123-45. doi: 10.1016/j.jgyn.2013.11.007. Epub 2014 Jan 13. J Gynecol Obstet Biol Reprod (Paris). 2014. PMID: 24433988 Review. French.
-
The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion.Contraception. 2006 Jul;74(1):26-30. doi: 10.1016/j.contraception.2006.03.005. Epub 2006 Apr 27. Contraception. 2006. PMID: 16781256 Review.
Cited by
-
Tribute to James Trussell (1949-2018).Contracept Reprod Med. 2019 Aug 9;4:15. doi: 10.1186/s40834-019-0096-y. eCollection 2019. Contracept Reprod Med. 2019. PMID: 31417769 Free PMC article. No abstract available.
-
Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.Eur J Contracept Reprod Health Care. 2016 Dec;21(6):436-442. doi: 10.1080/13625187.2016.1229765. Epub 2016 Sep 16. Eur J Contracept Reprod Health Care. 2016. PMID: 27636701 Free PMC article. Clinical Trial.
-
Postabortion Care: 20 Years of Strong Evidence on Emergency Treatment, Family Planning, and Other Programming Components.Glob Health Sci Pract. 2016 Sep 29;4(3):481-94. doi: 10.9745/GHSP-D-16-00052. Print 2016 Sep 28. Glob Health Sci Pract. 2016. PMID: 27571343 Free PMC article. Review.
References
-
- Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996;87:884–90. - PubMed
-
- Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338:1241–7. - PubMed
-
- Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception. 2003;67:463–5. - PubMed
-
- Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception. 2004;70:183–90. - PubMed
-
- Henderson JT, Hwang AC, Harper CC, Stewart FH. Safety of mifepristone abortions in clinical use. Contraception. 2005;72:175–8. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous